Germline APC Alterations May Predispose to Testicular Sex Cord-Stromal Tumors.
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
01 12 2023
01 12 2023
Historique:
medline:
15
11
2023
pubmed:
9
10
2023
entrez:
9
10
2023
Statut:
ppublish
Résumé
Sertoli cell tumor is a type of testicular sex cord-stromal tumor (TSCST) typically driven by gain-of-function CTNNB1 variants. Recently, molecular studies have identified TSCSTs (including Sertoli cell tumors) with loss-of-function APC variants, raising the possibility that germline APC alterations may predispose to TSCSTs. In this study, we evaluated 4 TSCSTs from 4 individual patients, including 3 APC -mutant neoplasms identified in prior studies (1 in a patient with familial adenomatous polyposis [FAP] and 2 in patients with unknown syndromic status) and 1 tumor of unknown mutational status diagnosed in a patient with known FAP. Three neoplasms were typical Sertoli cell tumors, and 1 was a malignant unclassified TSCT. All neoplasms exhibited diffuse nuclear beta-catenin expression. Non-neoplastic tissue could be obtained for DNA sequencing in the 3 Sertoli cell tumors. Comparative assessment of non-neoplastic and lesional tissue in these cases suggested that germline APC variants with subsequent inactivation of the gene (loss of heterozygosity) were the likely oncogenic driver of these Sertoli cell tumors. In the malignant unclassified TSCSTs, APC inactivation was also interpreted as the most likely driver event, and the germline origin of the variant was inferred using a recently published method. The results of this study suggest that pathogenic germline APC alterations (eg, FAP and variants thereof) may predispose to TSCSTs.
Identifiants
pubmed: 37811860
doi: 10.1097/PAS.0000000000002132
pii: 00000478-990000000-00246
doi:
Substances chimiques
Adenomatous Polyposis Coli Protein
0
beta Catenin
0
APC protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1432-1437Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Références
Waller A, Findeis S, Lee MJ. Familial adenomatous polyposis. J Pediatr Genet. 2016;5:78–83.
Koskenvuo L, Pitkäniemi J, Rantanen M, et al. Impact of screening on survival in familial adenomatous polyposis. J Clin Gastroenterol. 2016;50:40–44.
Perrone F, Bertolotti A, Montemurro G, et al. Frequent mutation and nuclear localization of β-catenin in Sertoli cell tumors of the testis. Am J Surg Pathol. 2014;38:66–71.
Xiao G-Q, Granato RC, Unger PD. Bilateral Sertoli cell tumors of the testis—a likely new extracolonic manifestation of familial adenomatous polyposis. Virchows Arch. 2012;461:713–715.
Corfield B, Francisco S, Koh M-A, et al. Testicular Sertoli cell tumour in a patient with familial adenomatous polyposis: a not-so-incidentaloma? Pathology (Phila). 2019;51:S77.
Rizzo NM, Sholl LM, Kao C-S, et al. Molecular correlates of aggressive behavior and biologic progression in testicular Sertoli cell tumor. Mod Pathol. 2023;36:100152.
Siegmund SE, Sholl LM, Tsai HK, et al. Clinicopathologic and molecular spectrum of testicular sex cord-stromal tumors not amenable to specific histopathologic subclassification. Mod Pathol. 2022;35:1944–1954.
Rizzo NM, Sholl LM, Idrees MT, et al. Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic features. Mod Pathol. 2021;34:1935–1946.
Necchi A, Bratslavsky G, Shapiro O, et al. Genomic features of metastatic testicular sex cord stromal tumors. Eur Urol Focus. 2019;5:748–755.
Garcia EP, Minkovsky A, Jia Y, et al. Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer. Arch Pathol Lab Med. 2017;141:751–758.
Sholl LM, Do K, Shivdasani P, et al. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016;1:e87062.
Abo RP, Ducar M, Garcia EP, et al. BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Res. 2015;43:e19.
Siegmund SE, Manning DK, Davineni PK, et al. Deriving tumor purity from cancer next generation sequencing data: applications for quantitative ERBB2 (HER2) copy number analysis and germline inference of BRCA1 and BRCA2 mutations. Mod Pathol. 2022;35:1458–1467.
Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis. 2009;4:22.
Zhang C, Ulbright TM. Nuclear Localization of β-catenin in Sertoli cell tumors and other sex cord-stromal tumors of the testis: an immunohistochemical study of 87 cases. Am J Surg Pathol. 2015;39:1390–1394.
Abell MR, Holtz F. Testicular and paratesticular neoplasms in patients 60 years of age and older. Cancer. 1968;21:852–870.
Karstensen JG, Burisch J, Pommergaard H-C, et al. Colorectal cancer in individuals with familial adenomatous polyposis, based on analysis of the Danish Polyposis Registry. Clin Gastroenterol Hepatol. 2019;17:2294.e1–2300.e1.
Heiskanen I, Luostarinen T, Järvinen HJ. Impact of screening examinations on survival in familial adenomatous polyposis. Scand J Gastroenterol. 2000;35:1284–1287.
Dinarvand P, Davaro EP, Doan JV, et al. Familial adenomatous polyposis syndrome: an update and review of extraintestinal manifestations. Arch Pathol Lab Med. 2019;143:1382–1398.
Orford K, Crockett C, Jensen JP, et al. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J Biol Chem. 1997;272:24735–24738.
Kato N, Shibuya H, Fukase M, et al. Involvement of adenomatous polyposis coli (APC) gene in testicular yolk sac tumor of infants. Hum Pathol. 2006;37:48–53.